Darnitsa pharmaceutical company plans to develop in foreign markets, in particular through the acquisition of companies or joint development. This was reported by head of the board of directors of Darnitsa Group Dmytro Shymkiv in Kyiv. He noted that the purchase of foreign companies is one of the “instruments to increase the share of exports.”
According to him, Darnitsa is currently conducting due diligence of several companies, and although Shymkiv did not provide details, he added that the company is studying the issue of acquiring companies not only abroad.
Currently, Darnitsa has about 365 registrations in foreign markets.
“Not all Ukrainian pharmaceutical manufacturers will withstand the requirements for 2D coding of pharmaceutical packaging. In 2020, we will see interesting processes in the Ukrainian market,” he said.
According to him, in 2020 the company plans to invest about EUR4 million in development and research.
As reported, in 2018 Darnitsa invested about EUR3.5 million in development and research, while annually the company invests about 10% of gross income in this direction.
Darnitsa pharmaceutical company is one of the ten largest pharmaceutical manufacturers in Ukraine and the top ten largest hospital suppliers. Its ultimate beneficiary is Hlib Zahoriy.
Monfarm pharmaceutical company (Cherkasy region) in January-June 2019 increased its net profit by 28.64% compared to the same period of 2018, to UAH 8.539 million.
According to the information disclosure system of the National Commission on Securities and the Stock Market, the company’s gross profit in the first half of the year increased by 8.12%, to UAH 30.084 million, and its net income decreased by 0.36%, to UAH 70.495 million.
As reported, Monfarm pharmaceutical company in 2017 reduced its net profit by 9.6% compared with 2017, to UAH 15.321 million.
PJSC Monfarm was established in 1994 through the corporatization and privatization of state enterprise Monastyrysche Pharmaceutical Plant, organized in 1986 on the basis of a distillery, as part of the Kyiv pharmaceutical association Darnitsa. At present, the range of medicines that Monfarm produces includes more than 70 types of drugs from various pharmacotherapeutic groups.
According to the state register, the ultimate beneficiary of the company is Yakiv Kuznetsov.
PJSC Farmak (Kyiv), among top three leaders of the pharmaceutical sector of Ukraine, in 2018 plans to increase the exports share to 33%.
The company told Interfax-Ukraine that in H1 2018 Farmak’s exports grew by 13% year-over-year, in particular, thanks to supplies to Uzbekistan (a rise by 20%), Belarus (by 124%), Kazakhstan (by 13%) and Kyrgyzstan (by 16%).
Sales of products to Russia remained at the level of 2017.
“We want to increase the export potential of the company by retaining the leading positions in Ukraine. It would lead to an increase in production, creation of new jobs, an increase in the amount of taxes paid. For Farmak, the markets of the European Union and Asia remain a priority,” Farmak Executive Director Volodymyr Kostiuk said.
In general, according to him, in 2017, Farmak exported products for $70 million. In 2017, Poland, Uzbekistan and Russia dominated the structure of foreign sales. In particular, sales to Poland accounted for 28.3% of total exports, Uzbekistan – 20.9% and Russia – 16.7%.
In 2017, the share of Farmak’s sales in foreign markets was 31%.
Farmak is a member of the Association Manufacturers of Medications of Ukraine (AMMU).
Public joint-stock company Farmak, the pharmaceutical company of Ukraine of the top three largest companies in the country, is mulling the possibility of acquiring a pharmaceutical company in Europe, acting CEO Volodymyr Kostiuk has said. “Now we are looking for a company which could be bought,” he told reporters.
Kostiuk said that this is the acquisition of an industrial company or a company with a product portfolio in Europe.
“Poland was the first step. Now we are looking at Hungary and Croatia. There is a concrete targeted profile. We are trying to meet it and select companies-candidates,” he said.
Kostiuk said that Farmak does not set the terms for acquiring the company and behaves thoughtfully regarding the cost of the asset.
“We are not in a hurry. We want to find the company that meets our plans as fully as possible,” he said.
In turn, Farmak Technical Director Andriy Hoi did not rule out that production of cancer treating medicines will be organized at the facilities of Farmak.
“These are very expensive medicines. They have a high production cost. These are highly active medications. Having several cancer treating medicines in our portfolio, including from post-Soviet solutions, we are working with leading Western companies regarding the localization of production of these medicines. We are thinking on starting a separate production line in the medium term outlook and a separate line of highly active medications,” he said.